Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 519 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07163611RecruitingPhase 2/Phase 3
Obinutuzumab for PLA2R antibodies in membranous nephropathy
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
NijmegenAges 18 years+ - NCT07159750Recruiting
Study on new migraine drugs in real life
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
Miami, FloridaAges 18 years+ - NCT07154342RecruitingPhase 3
Testing a new antibody for seasonal allergies
This trial tests an experimental antibody (IL4Rα monoclonal antibody) for people with seasonal allergic rhinitis (hay fever) that is not well controlled by standard treatments like nasal steroid sprays. The goal is to see if this new treatment can help reduce allergy symptoms during pollen season.
Wuhan, HubeiAges 18–75 - NCT07142239Recruiting
Blood markers in primary vs. secondary antiphospholipid syndrome
This study looks at three blood markers (MPV, PLR, and NLR) in people with antiphospholipid syndrome (APS) to see if they differ between primary APS (no other autoimmune disease) and secondary APS (with lupus or another autoimmune condition). It may help doctors better understand and manage APS.
Al Khārjah, Kharga OasisAges 18 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07131202RecruitingPhase 1/Phase 2
FL115 plus PD-1 antibody for advanced solid tumors
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–80 - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT07135427RecruitingPhase 4
Genes and vaccines in alpha-1 antitrypsin deficiency
This study looks at how genetic differences in alpha-1 antitrypsin deficiency affect immune response to a pneumonia vaccine. It may help find better ways to prevent lung infections.
Birmingham, AlabamaAges 19 years+ - NCT07128381RecruitingPhase 1/Phase 2
Axatilimab plus Ruxolitinib for Myelofibrosis and CMML
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
Houston, TexasAges 18 years+ - NCT07135453RecruitingPhase 4
Pneumonia vaccine study for healthy adults
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
Birmingham, AlabamaAges 18 years+ - NCT06932471RecruitingPhase 3
Study of a new drug for PNH patients with anemia despite current treatment
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07115654RecruitingPhase 2
A bispecific antibody trial for POEMS syndrome
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
TianjinAges 18–78 - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07103694Recruiting
Migraine drug database study
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
Milan, ItalyAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07089836Recruiting
Syphilis blood test study for at-risk and healthy people
This study tests two new blood tests for syphilis. It compares them to approved tests using blood from people who may have or had syphilis, including pregnant women, HIV-positive people, and healthy volunteers.
Lancaster, CaliforniaAges 13 years+ - NCT07093333RecruitingPhase 2
Testing a new antibody treatment for anti-NMDAR brain disease
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
SeoulAges 18–65 - NCT07087314RecruitingPhase 2
Study of an injection for nephrotic syndrome in children
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
Hangzhou, ZhejiangAges 6–18 - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07091305RecruitingPhase 2
Study of a new drug with chemotherapy for limited-stage small cell lung cancer
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
ShanghaiAges 18–75 - NCT06968442Recruiting
Obesity and severe COVID-19 study
This study looks at how obesity affects the body's response to severe COVID-19. It compares people with obesity to healthy-weight healthcare workers to understand differences in the immune system.
Rotterdam, South HollandAges 18–65
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 519 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.